Abstract Changes in DNA methylation in cancer have been heralded as promising targets
for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite …

T cells possess an array of functional capabilities important for host defense against
pathogens and tumors. T cell effector functions require the T cell antigen receptor (TCR) …

Background Ibrutinib has been approved by the Food and Drug Administration for the
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has …

Background Chemoimmunotherapy has led to improved numbers of patients achieving
disease response, and longer overall survival in young patients with chronic lymphocytic …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with
chronic lymphocytic leukemia. Most patients experience lymphocytosis, representing …

Purpose Non–small-cell lung cancer (NSCLC) is a tumor in which only small improvements
in clinical outcome have been achieved. The issue is critical for stage I patients for whom …

Epigenetic alterations are associated with normal biological processes such as aging or
differentiation. Changes in global epigenetic signatures, together with genetic alterations …

The comparison of DNA methylation patterns across cancer types (pan-cancer methylome
analyses) has revealed distinct subgroups of tumors that share similar methylation patterns …

Background The clinical course of prostate cancer (PCa) is highly variable, demanding an
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …